Scholarlink

<p>We previously reported that all doses of ibuzatrelvir, an oral SARS-CoV-2 M<sup>pro</sup> inhibitor, twice daily for 5 days significantly reduced viral RNA levels (viral load [VL]) from baseline compared with placebo among adults without risk factors for severe COVID-19 during the Omicron era (Clinicaltrials.gov NCT05799495). This post hoc exploratory analysis evaluated the impact of pre-existing antibody (Ab) levels on viral clearance by treatment group. Baseline anti-Spike (S) and neutralizing Ab (nAb) were positive in 99.6% and 82.1% of the participants, respectively. Higher baseline nAb levels were significantly associated with greater change from baseline in viral load at day 5 (d5 CFB-VL) only in placebo. Modeling projected that at a mean baseline Ab level 2-fold higher than observed, placebo-adjusted d5 CFB-VL by ibuzatrelvir 600 mg would be -0.72 log<sub>10</sub> copies/ml (95% CI: -1.29, -0.15) with nAb and -0.73 log<sub>10</sub> copies/ml (95% CI: -1.34, -0.12) with anti-S. This analysis suggests that day 5 VL reduction by ibuzatrelvir 600 mg would still be at least 5-fold greater than placebo, even at hypothetical 2-fold higher mean baseline Ab levels than were observed in this study.</p><p><i>Trial registration</i>: ClinicalTrials.gov NCT05799495</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Ibuzatrelvir potently reduced viral RNA levels despite a high rate of anti-S seropositivity: a post hoc analysis of serology of the phase 2b study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月8日

查看全文
  • Jin Hyang Kim,
  • Alex Knutson,
  • Justin Smith,
  • Shunjie Guan,
  • Luke F. Chen,
  • Mahta Mortezavi,
  • Abigail Sloan,
  • Anindita Banerjee,
  • Mary Lynn Baniecki,
  • Craig Hyde,
  • Charlotte Allerton,
  • Negar Niki Alami

摘要

We previously reported that all doses of ibuzatrelvir, an oral SARS-CoV-2 Mpro inhibitor, twice daily for 5 days significantly reduced viral RNA levels (viral load [VL]) from baseline compared with placebo among adults without risk factors for severe COVID-19 during the Omicron era (Clinicaltrials.gov NCT05799495). This post hoc exploratory analysis evaluated the impact of pre-existing antibody (Ab) levels on viral clearance by treatment group. Baseline anti-Spike (S) and neutralizing Ab (nAb) were positive in 99.6% and 82.1% of the participants, respectively. Higher baseline nAb levels were significantly associated with greater change from baseline in viral load at day 5 (d5 CFB-VL) only in placebo. Modeling projected that at a mean baseline Ab level 2-fold higher than observed, placebo-adjusted d5 CFB-VL by ibuzatrelvir 600 mg would be -0.72 log10 copies/ml (95% CI: -1.29, -0.15) with nAb and -0.73 log10 copies/ml (95% CI: -1.34, -0.12) with anti-S. This analysis suggests that day 5 VL reduction by ibuzatrelvir 600 mg would still be at least 5-fold greater than placebo, even at hypothetical 2-fold higher mean baseline Ab levels than were observed in this study.

Trial registration: ClinicalTrials.gov NCT05799495